Lancet 2015 Jan 3
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.
Abstract
Background
Most patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy, and prophylactic cranial irradiation, have persistent intrathoracic disease. We assessed thoracic radiotherapy for treatment of this patient group.
Methods
We did this phase 3 randomised controlled trial at 42 hospitals: 16 in Netherlands, 22 in the UK, three in Norway, and one in Belgium. We enrolled patients with WHO performance score 0-2 and confirmed ES-SCLC who responded to chemotherapy. They were randomly assigned (1:1) to receive either thoracic radiotherapy (30 Gy in ten fractions) or no thoracic radiotherapy. All underwent prophylactic cranial irradiation. The primary endpoint was overall survival at 1 year in the intention-to-treat population. Secondary endpoints included progression-free survival. This study is registered with the Nederlands Trial Register, number NTR1527.
Findings
We randomly assigned 498 patients between Feb 18, 2009, and Dec 21, 2012. Three withdrew informed consent, leaving 247 patients in the thoracic radiotherapy group and 248 in the control group. Mean interval between diagnosis and randomisation was 17 weeks. Median follow-up was 24 months. Overall survival at 1 year was not significantly different between groups: 33% (95% CI 27-39) for the thoracic radiotherapy group versus 28% (95% CI 22-34) for the control group (hazard ratio [HR] 0.84, 95% CI 0.69-1.01; p=0.066). However, in a secondary analysis, 2-year overall survival was 13% (95% CI 9-19) versus 3% (95% CI 2-8; p=0.004). Progression was less likely in the thoracic radiotherapy group than in the control group (HR 0.73, 95% CI 0.61-0.87; p=0.001). At 6 months, progression-free survival was 24% (95% CI 19-30) versus 7% (95% CI 4-11; p=0.001). We recorded no severe toxic effects. The most common grade 3 or higher toxic effects were fatigue (11 vs 9) and dyspnoea (three vs four).
Interpretation
Thoracic radiotherapy in addition to prophylactic cranial irradiation should be considered for all patients with ES-SCLC who respond to chemotherapy.
Funding
Dutch Cancer Society (CKTO), Dutch Lung Cancer Research Group, Cancer Research UK, Manchester Academic Health Science Centre Trials Coordination Unit, and the UK National Cancer Research Network.
Related Questions
How would you manage a treatment-naive patient who has painful vertebral lesions from ES-SCLC?
ES-SCLC is incurable. If they are in pain, treat their pain. Chemotherapy is palliative. TRT may extend life, but the average life expectancy with ES-SCLC is limited. Don't let patients in pain suffer when we have an effective way to treat them. I would consider very short courses - 1-2 fx SBRT (per...
Does omission of PCI influence your decision whether to offer consolidative thoracic radiation in ES-SCLC after chemo + immunotherapy?
This is one of those stories that has evolved over time with our improvements in technology.EORTC 08993 (the Slotman study) demonstrated both an improvement in the rate of symptomatic brain mets at 1 yr from 40% to 15%, and an improvement in 1 yr OS from 13% to 27%. However, a huge caveat here is th...
Would you offer radiation alone to localized recurrence of extensive stage small cell lung cancer while on maintenance immunotherapy or would you start alternative systemic therapy?
The role of local therapy for the treatment of patients with ES SCLC has been evaluated in a number of phase 3 trials. The first trial, which was published by Jeremic et al., PMID 10561263 over 20 years ago, reported a survival advantage for adding thoracic radiation to chemotherapy compared with ch...
For ES-SCLC with a distant cCR and local cPR after systemic therapy sustained for at least 1 year, how would you approach consolidative thoracic RT?
The CREST trial by Slotman referenced enrolled patients with the findings above after 4-6 cycles of chemotherapy, and required patients initiate radiation therapy within 6 weeks. If this patient truly has not progressed 1 year after chemotherapy, I am not clear on what the additional benefit of radi...
As consolidative thoracic radiation (cTRT) was prohibited on the seminal chemoimmunotherapy trials in ES-SCLC, how do you approach cTRT in practice?
There are two trials showing benefit for TRT for patients with ES-SCLC, one from Yugoslavia and one from the EORTC (though, the primary endpoint was not met). The Yugoslavian trial was not considered practice changing, while the EORTC study has made me consider adding TRT in certain patients, even w...
How do you sequence thoracic consolidation RT and PCI with incorporation of immunotherapy in ES-SCLC?
In the IMpower133 study, "during the maintenance phase, prophylactic cranial irradiation was permitted as per local standard-of-care, but thoracic radiation with curative intent or the intent to eliminate residual disease was not permitted. Palliative thoracic radiation was allowed. (quoting from th...
When is it too far out from CRT to the chest to be considered for PCI for limited-stage SCLC?
How about this answer that was not listed - "don't give it!" The evidence we hang our hat for PCI in SCLC is not just weak, it is also outdated. With the medical technology available they had at the time, it made logical sense that staging would miss brain metastases. ~50% of the studies in the meta...
Do you offer consolidative thoracic radiotherapy to patients with extensive stage SCLC who have a complete response to chemotherapy?
The CREST trial did not meet primary goal of improving one year survival, but it did improve 2 year OS. Looking at subset, achieving CR to chemo was an indicator of a group that "did not benefit". So the rest of the question (what volume, what dose etc) becomes irrelevant.
What fractionation do you use for consolidative chest RT in extensive stage SCLC?
3 Gy x 10 is arguably the standard of care.For patients with good performance status, and who do not have extensive disease outside of the thorax (which is clearly a judgment call), we consider 2.5 Gy x 20 with a 2 week break. This is a well-tolerated schedule with respect to esophagitis. For those ...
When is it appropriate to recommend SBRT directed to sites of oligometastasis (ex, single adrenal met) for a patient with extensive stage small cell s/p chemo and PCI?
May I play devil's advocate for one moment? I don't wholly disagree with @Dr. First Last btw, fwiw.1) Some people with SCLC can be cured. It appears that the application of a local therapy in limited stage SCLC increases the chance for long-term DFS (aka "a cure"). Five-year survival was doubled fro...
What is the role of radiation in a patient with limited stage small cell lung cancer initially treated with chemotherapy alone and received a complete response based on CT and PET-CT?
From the 1990's SCLC studies of Ralph Johnson at the Radiation Oncology Branch, and then a later NCI re-analysis of that 100 patoient data set, the pattern of concurrent for 3-4 weeks was better than a longer period of time, or a shorter period of time including sequencing for many cycles followed ...
Do you recommend prostate RT for patients with metastatic (M1) disease?
My short answer to this provocative question is “no, I don’t offer men with M1 disease local radiation unless there’s a palliative need.” Treating the primary in the asymptomatic M1 scenario, whether with RT or with surgery, is a major commitment of time, resources, and risk to the patient. The leve...
Should consolidative RT for extensive stage SCLC be given before, after, or concurrently with PCI?
Great question, and to my knowledge there's not a lot of data to guide this so I dont think there's a wrong answer.Before the CREST trial, my practice was to do PCI first, because I felt that the evidence for an OS benefit was much stronger, and it was therefore more improtant to get this completed ...
Should the incorporation of thoracic RT be standard in patients with extensive stage small cell lung cancer?
The jury is really still out on the issue of whether or not to add thoracic radiation therapy to prophylactic cranial irradiation (PCI) in patients with extensive-stage small cell lung cancer. The published data cited above, Slotman et al. in Lancet last Fall 2014, indicate that there may be an over...
Is it acceptable to treat newly diagnosed small cell lung cancer with limited brain metastasis with upfront SRS?
First, to be clear, there's not good evidence regarding the role of radiosurgery in small cell patients who have not had WBRT or PCI. In patients without brain metastases, there's a clearly defined and clinically significant survival benefit, which seems to result from both control of existing metas...